Tempest announces Senlang collaboration for in vivo CAR-T trial, reports $0.8M cash

Filed August 13, 2026 · Period ending August 13, 2026 · ~2 min read

Key Changes

• high

  Tempest partnered with Senlang Biotechnology to advance TPST-4003, a CD7-targeted in vivo CAR-T candidate, in an investigator-initiated trial enrolling ~10 patients with myasthenia gravis or multiple sclerosis in China; first patient dosing expected Q4 2026.

  Exhibit 99.1 view on EDGAR →
• high

  Cash and cash equivalents fell to $0.8 million at June 30, 2026 from $7.7 million at year-end 2025, driven by transaction costs from the February asset acquisition, partially offset by $1.7 million from a March private placement and $1.7 million from a Q2 warrant inducement.

  Exhibit 99.1 view on EDGAR →
• high

  Q2 2026 net loss was $5.2 million ($0.34 per share), down from $7.9 million ($2.07 per share) in Q2 2025; six-month R&D expenses fell to $1.9 million from $11.5 million year-over-year, but the company recorded $22.1 million in acquired in-process R&D expenses related to the February asset acquisition.

  Exhibit 99.1 view on EDGAR →